Abstract: In a conventional vessel anti-rolling apparatus, because a large memory capacity and a high-speed high-function computing processing unit are required, the cost of the vessel anti-rolling apparatus is caused to rise. A vessel anti-rolling control apparatus and an anti-rolling control method according to the present disclosure includes an azimuth controller that outputs a first steering-angle command value for making the vessel turn to an azimuth to which the vessel should travel, based on an azimuth command signal and a yaw-angle signal, an anti-rolling controller that outputs a second steering-angle command value for reducing rolling of the vessel, based on a rolling-angle signal, a rolling-angular-velocity signal, and a vessel-speed signal, and a steering-angle controller that controls a steering angle, based on the first steering-angle command value and the second steering-angle command value.

Abstract: A low thermal expansion cast steel having a sufficient strength even at a high temperature and having a low coefficient of thermal expansion, that is, a low thermal expansion cast steel comprising, by mass %, C: 0 to 0.100%, Si: 0 to 1.00%, Mn: 0 to 1.00%, Co: 8.0 to 13.0%, and Ni satisfying ?2.5×% Ni+85.5?% Co??2.5×% Ni+90.5 (% Ni and % Co respectively being contents of Ni and Co (mass %)) and having a balance of Fe and unavoidable impurities and having, upon being subjected to suitable heat treatment, a 0.2% proof stress of a tensile test at 300° C. of 125 MPa or more, having an average coefficient of thermal expansion at 25 to 300° C. of 4.0 ppm/° C. or less, and having a Curie temperature of 250° C. or more.

Abstract: An object of the present invention is to provide a low thermal expansion cast steel having sufficient strength even at a high temperature and a low coefficient of thermal expansion. The low thermal expansion cast steel of the present invention is obtained by suitably heat treating a cast steel comprising, by mass %, C: 0 to 0.10%, Si: 0 to 1.00%, Mn: 0 to 1.00%, Co: 13.00 to 17.50%, Ni satisfying ?3.5×% Ni+118%?Co?3.5×% Ni+121 (% Ni and %?Co respectively represent the contents of Ni and Co (mass %)), and a balance of Fe and unavoidable impurities so that the 0.2% proof stress in a tensile test at 400° C. becomes 100 MPa or more, the average coefficient of thermal expansion at 25 to 350° C. becomes 6.0 ppm/° C. or less, and the Curie temperature becomes 350° C. or more.

Abstract: An object of the present invention is to provide a low thermal expansion cast steel having a high yield strength at room temperature, a high rigidity, and a low coefficient of thermal expansion. The low thermal expansion cast steel of the present invention is obtained by suitably heat treating a cast steel comprising, by mass %, C: 0 to 0.1%, Si: 0 to 0.5%, Mn: 0 to 0.5%, S: 0 to 0.05%, Ni: 29.0 to 34.0%, Co: 0 to 8%, and a balance of Fe and unavoidable impurities so that the 0.2% proof stress becomes 350 MPa or more, the Young's modulus becomes 130 GPa or more, and the average coefficient of thermal expansion at 18 to 28° C. becomes 2.0×10?6/° C. or less.

Abstract: A low thermal expansion alloy having a high rigidity and a low thermal expansion coefficient comprising, by mass %, C: 0.040% or less, Si: 0.25% or less, Mn: 0.15 to 0.50%, Cr: 8.50 to 10.0%, Ni: 0 to 5.00%, and Co: 43.0 to 56.0%, S: 0 to 0.050%, and Se: 0 to 0.050% and having a balance of Fe and unavoidable impurities, the contents of Ni, Co, and Mn represented by [Ni], [Co], and [Mn] satisfying 55.7?2.2[Ni]+[Co]+1.7[Mn]?56.7 and the structure being an austenite single phase.

Abstract: A combination of drugs having a higher antitumor effect is provided. There is provided an adjuvant composition containing a pH sensitive carrier and a natural immunity-activating substance, the adjuvant composition being used to be administered in combination with an immune checkpoint inhibitor.

Abstract: Provided is a low thermal expansion alloy wherein martensitic transformation does not occur even at ?120° C. This low thermal expansion alloy contains, in mass %, 1.50-5.00% of Co, while containing Ni in such an amount that if [Ni] (mass %) is the content of Ni and [Co] (mass %) is the content of Co, [Co]??4×[Ni]+136 and [Co]??4×[Ni]+139 are satisfied, with the balance being made up of Fe and unavoidable impurities. This low thermal expansion alloy has an average thermal expansion coefficient of 0.5×10?6/° C. or less for the range of 0-30° C., while having a martensitic transformation temperature of ?120° C. or less.

Abstract: Provided is a low thermal expansion alloy wherein martensitic transformation does not occur even at ?120° C. This low thermal expansion alloy contains, in mass %, 1.50-5.00% of Co, while containing Ni in such an amount that if [Ni] (mass %) is the content of Ni and [Co] (mass %) is the content of Co, [Co]??4×[Ni]+136 and [Co]??4×[Ni]+139 are satisfied, with the balance being made up of Fe and unavoidable impurities. This low thermal expansion alloy has an average thermal expansion coefficient of 0.5×10?6/° C. or less for the range of 0-30° C., while having a martensitic transformation temperature of ?120° C. or less.

Abstract: According to the present invention, there is provided a complex in which a carrier and a physiologically active substance are integrated, the complex being conveniently obtainable, having excellent efficiency for the integration of a physiologically active substance, and having a satisfactory membrane disruptive function promoting effect. The complex according to the present invention is formed by supporting a physiologically active substance on an aggregate of a pH sensitive carrier, wherein the aggregate is formed by aggregating under acidic conditions.

Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.

Abstract: An adjuvant composition including a pH-sensitive carrier and an aluminum-containing substance is provided. An adjuvant that is highly safe and induces cell-mediated immunity effectively through cross-presentation is provided.

Abstract: A method for treating tumor or inflammation in a patient in need thereof by administering a pH sensitive drug which includes a pH sensitive carrier including at least one amphipathic substance, and a physiologically active substance supported in the pH sensitive carrier to induce the pH sensitive carrier to develop a membrane disruptive function and to deliver the physiologically active substance to the site.

Abstract: A low thermal expansion alloy having a high rigidity and a low thermal expansion coefficient comprising, by mass %, C: 0.040% or less, Si: 0.25% or less, Mn: 0.15 to 0.50%, Cr: 8.50 to 10.0%, Ni: 0 to 5.00%, and Co: 43.0 to 56.0%, S: 0 to 0.050%, and Se: 0 to 0.050% and having a balance of Fe and unavoidable impurities, the contents of Ni, Co, and Mn represented by [Ni], [Co], and [Mn] satisfying 55.7?2.2[Ni]+[Co]+1.7[Mn]?56.7 and the structure being an austenite single phase.

Abstract: [Problem] To provide a combination of drugs having a higher antitumor effect. [Solution] There is provided an adjuvant composition containing a pH sensitive carrier and a natural immunity-activating substance, the adjuvant composition being used to be administered in combination with an immune checkpoint inhibitor.

Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.

Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.

Abstract: The present invention relates to an adjuvant composition including a pH-sensitive carrier and an aluminum-containing substance. According to the present invention, there is provided an adjuvant that is highly safe and induces cell-mediated immunity effectively through cross-presentation.

Abstract: A method for treating tumor or inflammation in a patient in need thereof by administering a pH sensitive drug which includes a pH sensitive carrier including at least one amphipathic substance, and a physiologically active substance supported in the pH sensitive carrier to induce the pH sensitive carrier to develop a membrane disruptive function and to deliver the physiologically active substance to the site.

Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.

Abstract: A pH sensitive carrier which includes at least one pH sensitive compound selected from the group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, C27 bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof, and at least one amphipathic substance selected from the group consisting of a phosphatidylcholine having 10 to 12 carbon atoms, a polyoxyethylene sorbitan monofatty acid ester having 12 to 18 carbon atoms, a sorbitan fatty acid ester having 16 to 18 carbon atoms, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil and ?-tocopherol, and which is capable of developing a membrane disruptive function promoting effect.